Dr. Iilun Murphy is the Director of the Office of Generic Drugs (OGD) within FDA’s Center for Drug Evaluation and Research (CDER), a role she has held since June 2023. In this capacity, she leads the office responsible for ensuring that high-quality, affordable generic medicines are accessible to the American public.
Dr. Murphy brings nearly two decades of FDA experience to this position. Her career at the agency began as a medical officer in CDER’s Office of New Drugs, after which she held leadership roles at the Center for Tobacco Products. She returned to CDER in 2020 as OGD’s Deputy Director for Clinical and Regulatory Affairs before being appointed to her current directorship.
A board-certified pediatrician, Dr. Murphy received her B.A. from Cornell University and her M.D. from Stanford University School of Medicine. She completed her residency in pediatrics through the Harvard University and Boston University Combined Residency Program and practiced clinical pediatric medicine prior to joining the FDA. She remains actively engaged in medical education as an Assistant Clinical Professor of Pediatrics at George Washington University School of Medicine.
